|12:45–12:48||Welcome and introduction||Ulf Landmesser (Chair)|
|12:48-13:08||Inflammation in Atherosclerosis: translating science into practicable solution||Peter Libby|
|13:08-13:28||Clinical residual cardiovascular risk: What are the markers?||Wolfgang Koenig|
|13:28–13:43||Panel Discussion: Advancing standard of care in post-MI patients with elevated HsCRP||
|13:43-13:45||Summary and Closure||Ulf Landmesser|
The objective of the symposium is to educate on:
- The role of inflammation in atherosclerosis.
- That “residual inflammatory risk” is distinct from “residual cholesterol risk” and hence an independent risk factor for atherosclerosis.
- How residual inflammatory risk can be easily diagnosed with available biomarkers – e.g., elevated hsCRP.
- The role for tailored therapeutic strategies to reduce residual inflammatory risk to improve outcomes for post-MI patients.